Tructum (ANTIFUNGAL)

Quick links

Choose a section

Quick links to important sections

Advertisements

Tructum (ANTIFUNGAL)

Advertisements
Advertisements

Overview of Tructum (ANTIFUNGAL)

Quick Facts Property Description
Active Ingredient Ketoconazole
Pharmacological Class Azole Antifungal
Form Tablet (oral), Cream, Foam, Gel, Shampoo (topical)
General Purpose To combat infections caused by fungi and yeasts
Origin Synthetic Imidazole derivative

Tructum (ANTIFUNGAL) is a medication containing the active component Ketoconazole, a synthetic compound derived from Imidazole, which classifies it as an Azole Antifungal agent. This is a single-component product whose primary function is rooted in countering the growth of various pathogenic fungi and yeasts.


The Identity and Classification

Tructum is the non-proprietary designation for a drug specifically designed to manage fungal infections, distinguishing it from antibacterial or antiviral medications. Ketoconazole is utilized for its broad-spectrum activity against many fungal species. This confirms the medication is effective against a wide variety of infectious fungi and yeasts.

As a recognized Prescription-only (Rx) agent in its oral form, Ketoconazole is typically reserved for managing widespread internal systemic mycoses or severe superficial infections when other antifungal options are not available or tolerated. Its therapeutic effect is derived entirely from the Ketoconazole component.


Composition and Available Forms

Ketoconazole is made available in multiple dosage forms to accommodate different routes of administration. The medicine exists as an oral tablet intended for systemic use, as well as topical preparations, including cream, foam, gel, and shampoo. Ketoconazole serves as both a systemic and topical agent. This means the medicine can be used internally for widespread issues or externally for localized skin problems.

This distinction in form is crucial: the tablet relies on solid excipients for internal absorption, while the topical versions utilize aqueous or emulsifying bases to deliver the medication directly to the affected area. These varied forms ensure that the medicine can be strategically deployed to address fungal infections precisely where the pathology resides.


General Purpose and Mechanism

The general purpose of Tructum is to provide a powerful fungistatic action that halts the growth and reproduction of infectious fungi and yeasts. This benefit is achieved by compromising the structural framework of the fungal cells themselves. The high-level mechanism of effect involves the disruption of the fungal cell membrane by interfering with the synthesis of ergosterol, a crucial fatty substance required for membrane construction. By preventing this material from being created, Ketoconazole effectively destabilizes the fungal cell.

Regulatory References

  1. NIH: Ketoconazole - StatPearls
  2. NIH: Ketoconazole (LiverTox)
  3. MedlinePlus: Ketoconazole Topical
Advertisements

What side effects are possible with Tructum (ANTIFUNGAL)?

Possible Side Effects and Safety Information for Tructum (ANTIFUNGAL)

The official safety information for Tructum, as documented in governmental regulatory sources, is necessary to confirm its specific risk profile. In the absence of published, product-specific labeling for Tructum, safety information must be considered in the context of antifungal medicines generally, which can affect multiple organ systems.

Antifungal agents are often associated with adverse reactions that may range from common and manageable to serious and clinically significant, particularly with systemic use. The frequency of these effects is formally classified in regulatory texts, such as by System-Organ Class (SOC), which commonly include the Gastrointestinal system (nausea, vomiting, abdominal pain), Nervous System (headache, dizziness), and Skin/Subcutaneous Tissue (rash, itching, irritation).

Serious Adverse Reactions across the antifungal class can involve Hepatotoxicity (liver damage), Nephrotoxicity (kidney dysfunction), and severe cutaneous reactions, which require prompt medical evaluation. The risk of these more severe reactions is a key aspect of the drug’s overall safety profile.

Safety Monitoring typically involves laboratory tests to check liver and kidney function, especially during prolonged systemic exposure. Population-specific safety considerations often address use in patients with pre-existing hepatic or renal impairment, where dosing may need adjustment. Patients with a known allergy to antifungal agents may also face restrictions on use.

Adverse Reaction Category Examples of Adverse Reactions (Antifungal Class)
Common / Very Common Nausea, vomiting, diarrhea, abdominal pain, headache, skin rash
Serious / Clinically Significant Severe allergic reactions (anaphylaxis), Hepatotoxicity, Nephrotoxicity

All individuals prescribed Tructum should adhere to prescribed monitoring to manage potential risks defined by the official prescribing information.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Tructum (ANTIFUNGAL)


Overdose Scope

Documented overdose presentations: Anorexia, Nausea, Vomiting, Fatigue, and Jaundice are regulatory-listed signs of potential systemic overexposure, primarily related to acute liver injury.

Physiological systems affected (as stated in label): The Endocrine System (Adrenal Cortex), Hepatic System (Liver), and Cardiovascular System (Heart Rhythm) are officially documented as being affected.

Dose-related or exposure-related factors (if applicable): Risks of severe toxicity are associated with high systemic exposure. For accidental ingestion of topical forms, regulatory guidance advises against procedures that could lead to aspiration.

Population-specific overdose notes (if applicable): The oral form is contra-indicated in patients with pre-existing acute or chronic liver disease, signifying a heightened risk of severity in this population during overexposure.

Emergency-response statements (as written in official documents): Treatment is restricted to supportive and symptomatic measures because no specific antidote is known. Procedures may include gastric lavage with activated charcoal if performed promptly (within one hour of ingestion).

When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention for any suspected overdose. Emergency services should be contacted immediately if the affected person collapses, has a seizure, or has trouble breathing.


Overdose Classifications (High-Level)

Severity classification (as defined in official documents): Potential for Severe or Fatal Hepatotoxicity and Life-threatening Ventricular Dysrhythmias.

Regulatory basis (EMA / FDA / etc.): EMA Summary of Product Characteristics and FDA Prescribing Information.

Overdose-context constraints (as defined in official documents): Continuous monitoring of Liver Function Tests (LFTs), ECG, blood pressure, and fluid/electrolyte balance may be required.


Resulting Overdose Structure

Official overdose statements:

  • Immediate medical attention is required for suspected overdose due to the potential for severe liver injury and adrenal insufficiency.
  • No specific antidote is known, and management is strictly defined as supportive and symptomatic treatment.
  • Overdose manifestations may include jaundice, fatigue, and gastrointestinal symptoms like nausea and vomiting.
  • Continuous ECG monitoring is required due to the documented risk of cardiac dysrhythmias.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by listing specific systemic manifestations and emphasizing the critical risks of severe liver damage and cardiac toxicity from high exposure. The profile mandates seeking immediate medical help and informs prescribers that because no specific antidote is known, clinical management focuses strictly on supporting the patient with symptomatic measures and continuous physiological monitoring.

Advertisements

Therapeutic Uses of Tructum (ANTIFUNGAL)

Tructum (ANTIFUNGAL) is commonly used across domains where additional symptomatic support is needed for fungal and yeast-related skin conditions.

The therapeutic action is relevant for managing conditions characterized by periods of heightened symptoms, including Seborrheic Dermatitis, Dandruff, ringworm (Tinea Corporis/Cruris), Tinea Pedis (athlete's foot), and Tinea Versicolor. The medication is applied in scenarios where additional management of discomfort is required for symptoms such as flaking, scaling, persistent itching, and visible rashes. For severe systemic mycoses (internal fungal diseases), the oral form is considered relevant in contexts involving a heightened systemic burden, providing support that helps ease the overall symptom burden.

“The focus is on providing symptomatic relief that helps patients cope more steadily with symptom fluctuations and helps improve day-to-day comfort during symptomatic periods.”

Quick Fact: Support for Key Symptom Domains
Topical (Skin/Scalp): Is used for managing groups of symptoms related to inflammatory or irritative states.
Oral (Systemic): Supports patients during episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus Drug Information on Ketoconazole Topical
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Tructum (Ketoconazole) — Official Regulatory Information

Category Oral Tablet (Systemic Use) Topical Preparations (Cream, Shampoo, Gel)
Populations for whom use is allowed Adults with severe endemic mycoses who have failed or are intolerant to alternatives. Adults and children 12 years of age and older for approved superficial conditions.
Populations for whom use is contraindicated Patients with acute or chronic liver disease, known hypersensitivity, or QTc prolongation risk. Persons with known hypersensitivity to formulation components.
Age-related eligibility rules Safety and effectiveness not established in children younger than 2 years. Safety and effectiveness not established in children younger than 12 years.
Pregnancy and lactation eligibility status Contraindicated (per some regulatory agencies) or labeled Pregnancy Category C. Labeled Pregnancy Category C.

Eligibility Classifications (High-Level)

Classification Details
Eligibility severity classification Absolute Contraindication (Liver disease, QTc risk, Hypersensitivity). Use Not Established (Specific pediatric age groups).
Eligibility-context constraints The oral tablet use is restricted to cases where alternatives are unavailable or not tolerated and is not indicated for superficial infections.

Resulting Eligibility Structure

  • The oral tablet is contraindicated in patients with acute or chronic liver disease or any risk of QTc prolongation.
  • The systemic use is restricted solely to patients with severe endemic mycoses when other effective therapies are not tolerated.
  • Use is not established for the oral tablet in children younger than 2 years of age or for topical preparations in children younger than 12 years of age.

Connection to the Overall Eligibility Profile

Regulatory documents establish a highly limited and conditional eligibility profile for the oral tablet, mandating that the medicine is reserved for a restricted patient population who meet specific criteria regarding disease severity and lack of alternatives, while strictly prohibiting its use in individuals with liver impairment or cardiac QTc risks.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Tructum (Ketoconazole) is largely defined by its function as a potent inhibitor of the CYP3A4 enzyme, a regulatory mechanism that is officially documented to significantly increase the plasma concentrations of many co-administered medicines. This pharmacokinetic interaction necessitates numerous label restrictions, including specific contraindicated combinations that must not be used concurrently.

Officially prohibited combinations include certain antiarrhythmics (e.g., Dronedarone, Quinidine), specific HMG-CoA reductase inhibitors (e.g., Lovastatin, Simvastatin), and some psychotropic agents (e.g., Pimozide, Lurasidone). These combinations carry a high risk of severe adverse events, such as cardiac dysrhythmias or rhabdomyolysis, as stated in regulatory documents.

Absorption-related constraints require special administration timing for oral Tructum. Antacids, H2-receptor antagonists, and other gastric acid reducers must be administered at least two hours after Tructum to maintain adequate drug absorption. Furthermore, regulatory information advises against co-administration with substances that may pose an additive risk of liver injury, particularly alcoholic beverages, due to the potential for a disulfiram-like reaction and increased hepatotoxicity risk. Grapefruit juice and the herbal product St. John's Wort are also noted for their potential to alter Ketoconazole exposure.

Advertisements

Mechanism of Action

The mechanism of action of Tructum involves the selective inhibition of a key fungal enzyme, lanosterol 14-alpha-demethylase (CYP51). This interaction is a form of competitive enzyme inhibition.

This specific blockade halts the metabolic pathway necessary for the biosynthesis of ergosterol, the primary stabilizing sterol within the fungal cell membrane. The resulting deficit of ergosterol, coupled with the accumulation of abnormal, toxic 14alpha-methylated sterol precursors, fundamentally destabilizes the fungal cell's outer architecture.

This structural failure increases membrane permeability and compromises essential membrane-bound functions, which constitutes the downstream mechanistic cascade. The overall system-level physiological consequence for the organism is the induction of a fungistatic physiological state, arresting cell growth and proliferation. This limitation of organism expansion establishes a physiological context compatible with host organism clearance processes.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Tructum (Ketoconazole)

Ketoconazole, the active component in Tructum, is administered through distinct routes based on the prescribed formulation: Oral for systemic therapy and Topical (cream, foam, gel, shampoo) for external application. The oral tablet is generally reserved for systemic fungal infections in patients who have failed or are intolerant to other effective therapies.

Standard Adult Dosing and Frequency

Administration Route Standard Regimen Frequency and Duration Context
Oral Tablet (200 mg) Initial dose is 200 mg once daily; may be increased to a maximum of 400 mg once daily Treatment duration is typically prolonged, such as six months
Topical Cream/Foam Applied to affected areas. Once daily (e.g., Tinea Corporis) or Twice daily (Seborrheic Dermatitis)
Topical Shampoo (2%) Apply, lather, and leave in place for 5 minutes before rinsing. Treatment for Tinea Versicolor is often a single application

Contextual Use Instructions

The oral tablet must be taken with a meal to ensure optimal absorption. If a patient has reduced stomach acidity (achlorhydria), the tablet should be administered with an acidic beverage to assist dissolution. For all topical forms, the use is strictly external. The topical foam is flammable, and users must avoid heat or flame during and immediately after application.

Population Adjustments

For pediatric use, dosing of the oral tablet in children over 2 years of age is calculated based on body weight, typically 3.3 to 6.6 mg/kg/day. Standard prescribing guidelines do not specify dosage modifications for adult patients with renal or hepatic impairment.

Advertisements

Recent Clinical Evidence

Tructum (ANTIFUNGAL): Recent Clinical Evidence

Evidence for Use in Superficial Fungal Infections (Topical Forms)

The evidence base for Tructum's topical forms (creams, shampoos, and gels) relies heavily on double-blind Randomized Controlled Trials (RCTs) and systematic reviews for localized conditions like Dandruff, Seborrheic Dermatitis, and Tinea. Research examined outcomes related to physical discomfort (e.g., scaling and itching) and changes in visible markers of the condition over short-term intervals. Limitations are noted regarding evidence quality variability and insufficient data for the youngest pediatric populations.

Evidence for Use in Widespread Systemic Mycoses (Oral Tablet)

The evidence for treating severe endemic mycoses (e.g., Histoplasmosis or Coccidioidomycosis) is generally categorized as Low. The research base consists primarily of older clinical trials and retrospective observational studies. These studies research examined high-level outcomes related to systemic or functional imbalance, often focusing on complex patient cohorts, including those with a history of inadequate response to other treatments. Comparative evidence is lacking against many of the newer, first-line treatments now available.

Long-Term Studies and Follow-Up Data

For superficial infections, the follow-up durations were limited to the immediate post-treatment period, meaning long-term outcomes are not fully established regarding patterns of recurrence or the maintenance of measured changes. For systemic use, observational periods were longer, tracking complex patient cohorts, but follow-up durations were limited in prospective, large-scale controlled trials.

Evidence in Special Populations

Research studies explored the use of Tructum in several specific patient groups. For the oral tablet, studies monitored outcomes in cohorts of immunocompromised patients. For topical forms, studies included adolescents and children (aged ge 2 years). However, data for certain groups remain insufficient, particularly for the youngest age groups.

What is Still Uncertain About Tructum (ANTIFUNGAL) Research

The evidence highlights what is known—and what is still uncertain. For the systemic oral formulation, comparative evidence is lacking to definitively place it alongside newer antifungal agents. Additionally, sample sizes were modest in some of the older or more specific studies. Findings describe group patterns, not personal outcomes. Research provides context but not individual predictions.

Key Studies & References

  1. Ketoconazole (General Overview and Classification) - StatPearls [Internet]
  2. Ketoconazole Topical - MedlinePlus Drug Information
  3. Ketoconazole - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tructum (ANTIFUNGAL) (FAQ)

Q: Does Tructum cause tiredness or drowsiness?

Official information indicates that unusual tiredness or weakness may occur with Tructum oral tablets. Sleepiness or unusual drowsiness has also been noted as a rare side effect in post-marketing reports, meaning it has been reported by users after the medicine was available for general use.


Q: Does Tructum interact with birth control pills?

The oral tablet form of Tructum (Ketoconazole) is known to be a strong enzyme inhibitor (specifically CYP3A4). This means it can alter the blood levels of certain hormonal contraceptives (such as levonorgestrel), which may affect how the contraceptive works. Regulatory documents indicate that due to this interaction, the combined use may require clinical consideration for dose adjustments and patient monitoring.


Q: What should I do if I miss a dose of Tructum?

According to regulatory-approved patient information, if a dose of the oral tablet is missed, it is generally recommended to be taken as soon as it is remembered. However, if it is close to the time for the next dose, the missed dose is typically skipped. Official guidance indicates that a double dose should not be taken to compensate for a missed dose.


Q: Do you have to take Tructum at the same time every day?

The oral tablet is usually administered once a day and is typically administered at approximately the same time every day. This consistency is generally described as being important for maintaining the intended level of medication.


Q: If I feel better, is it okay to stop using Tructum early?

Official prescribing information describes that treatment is generally continued for the full duration specified. The regulatory text indicates that discontinuing the medication prematurely carries a recognized risk that the infection may not be fully resolved.


Q: Does Tructum affect sun sensitivity?

Some official patient information, particularly for topical formulations, suggests that the area where Tructum is applied might be more sensitive to the sun. The official documentation includes information that protection from direct sunlight may be a consideration to help mitigate the potential risk of developing a rash or skin reaction.


Q: Is Tructum suitable for elderly patients?

In some clinical trials, the overall safety and effectiveness profile in older individuals (aged 65 and over) was not significantly different from younger subjects. However, official documents caution that greater sensitivity in some older individuals cannot be ruled out. The labeling indicates that patient monitoring may be a consideration in this population.


Q: Is Tructum prescribed for nail fungus?

The oral tablet form of Tructum is not indicated for the treatment of onychomycosis (nail fungus). The oral formulation is generally reserved only for certain severe systemic (widespread) fungal infections due to the conditional and restricted eligibility profile for the oral formulation.


Q: Has Tructum been recalled or taken off the market anywhere?

Official governmental records, such as the FDA Federal Register, have noted that certain topical formulations of Ketoconazole (the active ingredient in Tructum) were not withdrawn from sale for reasons related to safety or effectiveness. This information serves to clarify the official regulatory status of these products.


Q: Does Tructum have a taste or odor?

The active ingredient in Tructum (Ketoconazole) is generally described as having a characteristic odor. The final product's specific taste and smell will depend on the other inactive ingredients, or excipients, used in the specific formulation (tablet, cream, shampoo, etc.).


Q: Is Tructum known to cause hair loss?

Official post-marketing reports indicate that hair loss (alopecia) and abnormal hair texture have been reported, particularly with topical formulations of the medication. This is a reported side effect that has been noted in official reports.


Q: Are there any official warnings about Tructum affecting mood or anxiety?

Official post-marketing reports list rare adverse reactions for the active ingredient that affect the nervous system, including insomnia (trouble sleeping) and nervousness. More serious, though rare, reports have also included confusion and suicidal tendencies.


Q: What is the risk of resistance developing to Tructum, based on studies?

Some studies cited in regulatory documents suggest that the development of resistance to the active ingredient in Tructum by common fungi (dermatophytes and yeasts) has not been reported in those specific trials. However, antifungal drug resistance is a challenge that is generally recognized in medicine.


Q: Does Tructum contain any common allergens like gluten or lactose?

Formulations of Tructum contain various excipients (inactive ingredients) in addition to the active drug. Official labels state that patients with a known hypersensitivity or allergy to the active ingredient or any of the product's excipients are contraindicated (should not use the product). The specific excipients used vary by product type (e.g., tablet vs. shampoo).


Q: How long does Tructum stay in the body after the last use?

Official information states that the serum half-life of the oral active ingredient is typically between approximately 3 to 10 hours. The half-life represents the time required for the amount of medication in the bloodstream to be reduced by half. This time can be influenced by how long the medication has been taken and whether it is administered with food.

Advertisements

How should Tructum (ANTIFUNGAL) be stored and disposed of?

How to Store and Dispose of Tructum (ANTIFUNGAL)

The storage and disposal of this medication, which contains Ketoconazole, must follow specific regulatory requirements to ensure product integrity and public safety.


Official Storage Requirements

Ketoconazole must be stored at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and excessive heat, and the topical forms must not be frozen. All forms must be kept in their original, tightly closed container.


Handling and Disposal

Child safety is mandatory: the medication must be stored out of the reach and sight of children. The topical foam formulation requires special handling as it is flammable and must be kept away from fire and flame. Expired or unused medication must be disposed of properly and should not be flushed down a toilet or drain unless instructed otherwise by drug disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tructum (ANTIFUNGAL) found in:

A-Z Index: